Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Forest Laboratories, Inc.    

FOREST LABORATORIES, INC.
Mes dernières consult.
Most popular
  Report  
SummaryNewsCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Forest Labs 4Q Net Falls 40% As Lexapro Patent Expires; Has Upbeat Year View

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2012 | 02:41pm CEST

Forest Laboratories Inc.'s (>> Forest Laboratories, Inc.) fiscal fourth-quarter earnings fell 40% as generic competition to its depression treatment Lexapro hurt sales, though margins improved.

The company forecast fiscal 2013 earnings of $1.20 to $1.35 a share, while analysts surveyed by Thomson Reuters expect $1.08 a share.

Like many drug makers, Forest Labs is looking to bolster its pipeline as it lost patent protection on its main money maker, Lexapro, on March 14, and its No. 2 drug, the Alzheimer's and dementia treatment Namenda, loses exclusivity in 2015. The company acquired Clinical Data Inc. last year, in hopes antidepressant Viibryd may help offset lower Lexapro sales, and earlier this month it bought the high-blood pressure drug Bystolic from Johnson & Johnson's (JNJ) Janssen Pharmaceutica NV for a one-time cash payment of $357 million, eliminating all future royalties.

Sales of Lexapro dropped 40% to $355.8 million in the most recent quarter, while Namenda sales increased about 20% to $393.1 million.

For the quarter ended March 31, Forest Labs reported a profit of $192.7 million, or 72 cents a share, down from $322.5 million, or $1.12, a year earlier. Excluding items such as acquisition-related amortization, earnings fell to 78 cents from $1.14. Revenue dropped 7.3% to $1.06 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of 70 cents on revenue of $1.02 billion.

Operating margin rose to 79.8% from 64.1% as input costs dropped 8.4%.

The company increased its selling, general and administrative costs 17% to support new products, such as Viibryd and the chronic obstructive pulmonary disease treatment Daliresp, which became available in June.

Shares closed Monday at $33.64 and were inactive premarket. The stock is up 11% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

Stocks mentioned in the article : Forest Laboratories, Inc.
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.14% 122.84 Delayed Quote.-12.27%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FOREST LABORATORIES, INC.
2014FOREST LABORATORIES : Actavis and Forest Receive U.S. FTC Clearance for Actavis&..
BU
2014FOREST LABORATORIES : Actavis and Forest Announce Preliminary Stockholder Merger..
BU
2014Affiliated Managers Group to Join S&P 500
DJ
2014U.S. HOT STOCKS : Hot Stocks to Watch
DJ
2014FOREST LABORATORIES : Announces Positive Topline Results from Three Phase III Tr..
BU
2014FOREST LABORATORIES : Labs Posts Positive Results for Anxiety Disorder Drug
DJ
2014FOREST LABORATORIES : Actavis and Forest Laboratories Announce Appointment of C...
BU
2014FOREST LABORATORIES : to Present Cariprazine Data at the International College o..
BU
2014FOREST LABORATORIES : Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA®..
BU
2014FOREST LABORATORIES : COPD Foundation Releases Groundbreaking COPE Survey Result..
BU
More news
Sector and Competitors
1st jan.Capitalization (M$)
FOREST LABORATORIES, INC.0
JOHNSON & JOHNSON-12.27%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-12.58%191 785
MERCK AND COMPANY8.90%165 373